The global market for liver disease treatments amounted to nearly $8.4 billion in 2007 and is expected to increase to $9.8 billion in 2014, for a compound annual growth rate (CAGR) of 3.0%
The treatment for hepatitis is the largest segment of the market, amounting to about $4.6 billion in the last three years, and is expected to reach $4.8 billion in 2014.
Sales of targeted therapies were comparatively less in 2008, but this market has the potential to grow faster mainly because of the increased incidence of hepatitis C in developing countries.
(0 items)
